Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.37 |
| ▸ | ITGA2 | P17301 | 3/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1678089 | 0.92 | CHRM3 (0.38) | CHRM3HRH1F2CYP1A2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL1678087 | 0.92 | CHRM3 (0.38) | CHRM3HRH1F2CYP1A2ALDH1A1 | |
| SCHEMBL2184889 | 0.87 | HRH1 (0.46) | CHRM3HRH1CYP1A2ALDH1A1 | |
| SCHEMBL32665351 | 0.87 | HRH1 (0.46) | CHRM3HRH1CYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1677150 | 0.86 | HRH1 (0.45) | CHRM3HRH1CYP1A2ALDH1A1 | |
| SCHEMBL26931611 | 0.76 | GAA (0.46) | CYP1A2ALDH1A1CYP2C9 | |
| SCHEMBL30728974 | 0.76 | GAA (0.46) | CYP1A2ALDH1A1CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL30449219 | 0.73 | ITGB3 (0.48) | ITGB3ITGA2BITGA2CYP1A2ALDH1A1 | |
| SCHEMBL1676960 | 0.73 | L3MBTL1 (0.44) | CYP1A2ALDH1A1CYP2C9 | |
| SCHEMBL24130978 | 0.73 | ALDH1A1 (0.43) | CYP1A2ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518934-B2 | Oxycarbamoyl compounds and the use thereof | SHONOGI & CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2346820-B1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-02-13 | — | — | EP | disclosed |
| EP-2346820-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | Shionogi & Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| WO-2009151152-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | CACNA1B, ORAI1, CACNA1I | CHRM3 311/4885HRH1 1133/4885F2 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.